AKBA Akebia Therapeutics, Inc.
Healthcare$1.04+1.96%ClosedMarket Cap: $279.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
9.95
P/S
1.18
EV/EBITDA
39.04
DCF Value
$-3.80
FCF Yield
21.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.9%
Operating Margin
2.3%
Net Margin
-8.8%
ROE
-62.7%
ROA
-5.7%
ROIC
2.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $53.5M | 76.4% | $-4.7M | $-9.1M | $— | — |
| Q4 null | $57.6M | 78.8% | $-8.6M | $-12.2M | $— | — |
| FY null | $236.2M | 83.3% | $23.5M | $-5.3M | $— | — |
| Q3 null | $58.8M | 83.5% | $4.4M | $540.0K | $— | — |
| Q2 null | $62.5M | 84.1% | $14.1M | $247.0K | $— | — |
| Q1 null | $57.3M | 86.7% | $13.5M | $6.1M | $— | — |
| Q4 null | $46.5M | 56.2% | $-14.3M | $-22.8M | $— | — |
| FY null | $160.2M | 60.6% | $-50.5M | $-69.4M | $— | — |
| Q3 null | $37.4M | 62.2% | $-12.5M | $-20.0M | $— | — |
| Q2 null | $43.6M | 81.0% | $-8.7M | $-8.6M | $— | — |
| Q1 null | $32.6M | 91.7% | $-14.9M | $-18.0M | $— | — |
| Q4 2023 | $56.2M | 66.8% | $1.4M | $614.0K | $0.00 | — |